Orchestra Biomed Holdings Inc
NASDAQ:OBIO
Orchestra Biomed Holdings Inc
Orchestra Biomed Holdings, Inc. engages in the provision of biomedical technologies to patients through risk-reward-sharing partnerships with medical device companies. The company is headquartered in New Hope, Pennsylvania. The company went IPO on 2020-08-04. The company is engaged in developing technologies for patients through risk-reward sharing partnerships with medical device companies. Its flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) and Virtue Sirolimus AngioInfusion Balloon (SAB). BackBeat CNT is a bioelectronic treatment for hypertension that is designed to drive an immediate reduction in blood pressure while simultaneously modulating autonomic nervous system responses to maintain the reduction. Virtue SAB is a patented drug/device combination product candidate in development for the treatment of certain forms of artery disease that is designed to deliver an investigational, extended-release formulation of sirolimus, SirolimusEFR, to the vessel wall during balloon angioplasty without any coating on the balloon surface or the need to leave a stent or other permanent implant in the artery.
Orchestra Biomed Holdings, Inc. engages in the provision of biomedical technologies to patients through risk-reward-sharing partnerships with medical device companies. The company is headquartered in New Hope, Pennsylvania. The company went IPO on 2020-08-04. The company is engaged in developing technologies for patients through risk-reward sharing partnerships with medical device companies. Its flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) and Virtue Sirolimus AngioInfusion Balloon (SAB). BackBeat CNT is a bioelectronic treatment for hypertension that is designed to drive an immediate reduction in blood pressure while simultaneously modulating autonomic nervous system responses to maintain the reduction. Virtue SAB is a patented drug/device combination product candidate in development for the treatment of certain forms of artery disease that is designed to deliver an investigational, extended-release formulation of sirolimus, SirolimusEFR, to the vessel wall during balloon angioplasty without any coating on the balloon surface or the need to leave a stent or other permanent implant in the artery.
